ICAD Sep 2024 2.500 put
| Previous close | 1.1500 |
| Open | 1.1500 |
| Bid | 0.9500 |
| Ask | 1.1500 |
| Strike | 2.50 |
| Expiry date | 2024-09-20 |
| Day's range | 1.1500 - 1.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
GlobeNewswireiCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with in
- GuruFocus.com
icad Inc (ICAD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth and Operational ...
Discover how icad Inc achieved a 14% revenue increase and improved operational metrics in the first quarter of 2024.
- GlobeNewswire
iCAD Reports Financial Results for First Quarter Ended March 31, 2024
NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10%Total revenues were $5.0 million, up 14%Gross Profit Margin % was 83%, up from 82%GAAP Net Loss from
